Osteocalcin was shown to be a potential biomarker for metastatic malignancies such as breast cancer [30], prostate cancer [31], hepatitis B virus-related hepatocellular carcinoma [32], or other bone-derived tumors. This evidence concerns the gene BGLAP and breast carcinoma.